While biologics targeting extracellular cytokines such as IL-4 and IL-13 have demonstrated substantial clinical benefit, there is increasing interest in small molecule therapies capable of modulating intracellular signaling pathways integral to AD pathogenesis. Here, IL13 is linked to Alzheimer disease.